Skip to main content
. Author manuscript; available in PMC: 2022 Jun 27.
Published in final edited form as: Biochim Biophys Acta Mol Cell Res. 2021 May 1;1868(8):119047. doi: 10.1016/j.bbamcr.2021.119047

Fig. 3.

Fig. 3.

Alteration frequency of CREBBP/EP300 in the top 10 most frequently altered cancers. In non-melanoma skin cancer 35.26% of patients (183/519), 29.68% of bladder urothelial carcinoma patients (122/411), 28.77% of bladder/urinary tract cancer patients (21/73), 27.27% of penile cancer patients (3/11), 23.98% of bladder cancer patients (235/980), 23.53% of anal cancer patients (8/34), 21.51% of cervical squamous cell carcinoma patients (54/251), 21.16% of endometrial cancer patients (124/586), 21.05% of vaginal cancer patients (4/19), and 18.75% of small cell lung cancer patients (57/304).